Value of Exhaled Nitric Oxide (FeNO) And Eosinophilia During the Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospital Admission

References

• Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, Riesco, JA Trigueros JA, Piñera P, Simón A, et al. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol. 2012;48:247–57.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, FAbbri LM, Martinez FJ, Nishimura M, et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of COPD. Am J Respir Crit Care Med. 2013;187(4):347–65.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agüero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331–7.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–35.
   PubMed Web of Science ®Google Scholar
• Cosío BG, Soriano JB, López-Campos JL, Calle-Rubio M, Soler-Cataluña JJ, De-Torres JP, Marin JM, Martinez Gonzalez C, De Lucas P, Mir I, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016;149:45–52.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Alcázar B, Álvarez FJ, Bazús T, Calle M, Casanova C. What pulmonologists think about the asthma-COPD overlap syndrome (ACOS). Int J Chron Obstruct Pulmon Dis. 2015;10:1321–30.
   PubMed Web of Science ®Google Scholar
• Gelb AF, Barnes PJ, George SC, Ricciardolo FL, Zamel Z. Review of exhaled oxide in chronic obstructive pulmonary disease, J Breath Res. 2012;6(4):47–101.
   Web of Science ®Google Scholar
• Kunisaki KM. Exhaled nitric oxide and steroid responses in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(5):523–4.
   PubMed Web of Science ®Google Scholar
• Abba AA. Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann Thorac Med. 2009;4(4):173–81.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2012;138(3):682–92.
   Web of Science ®Google Scholar
• Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–54.
   PubMed Web of Science ®Google Scholar
• Wagener AH, De Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, Sterk PJ. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–20.
   PubMed Web of Science ®Google Scholar
• Soter S. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013;36(5):1178–85.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, Locantore N, Agustí A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–700.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
   PubMed Web of Science ®Google Scholar
• Sumino H, Sato K, Sakamaki T, Masuda H, Nakamura T, Kanda T, Nagai R. Decreased basal production of nitric oxide in patients with heart disease. Chest. 1998;2:317–22.
   Google Scholar
• Kakoki M, Matsumoto A, Nagata D, Kobayakawa N, Kimura K, Momomura S, Hirata Y. Analysis of nitric oxide in the exhaled air of patients with chronic glomerulonephritis. Clin Nephrol. 1999;52:83–90.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaelli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, Ricciardolo FL. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:271918. doi: 10.1155/2014/271918
   PubMed Web of Science ®Google Scholar
• ATS/ERS. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–30.
   PubMed Web of Science ®Google Scholar
• Kharinotov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir Soc Task Force Eur Respir J. 1997;10:1683–9.
   PubMed Web of Science ®Google Scholar
• Fortuna AM, Feixas T, Casan P. Determinación de óxido nítrico en aire espirado(FENO) mediante un equipo portátil (NIOX-MINOR Aerocrine) en población sana. Arch Bronconeumol. 2007;43(3):176–9.
   PubMedGoogle Scholar
• Agustí AG, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1999;14(3):523–8.
   PubMed Web of Science ®Google Scholar
• Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzelli S, Vestbo J. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J. 2013;41(1):12–17.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–5.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–74.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Greening NJ, Harvey-Dunstan TC, Willians JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest. 2016;150(2):320–8.
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and the frequency of severe acute exacerbations in COPD patients. Respirology. 2010;15(3):472–7.
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–73.
   PubMed Web of Science ®Google Scholar
• Alcázar-Navarrete B, Romero-Palacios PJ, Ruiz-Sancho A, Ruiz-Rodriguez O Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide. 2016;54:67–72.
   PubMed Web of Science ®Google Scholar